Key Takeaway
Ribitol and ribose produced different muscle-metabolite profiles in FKRP-mutant mice. The study raises research questions and does not establish human safety, dosing, or clinical benefit.
Evidence Summary
Ribitol and ribose treatments differentially affect metabolism of muscle tissue in FKRP mutant mice
Preclinical metabolomics comparison of ribitol and ribose exposure in an FKRP-mutant mouse model.
otherTherapy DevelopmentTrial ReadinessClinicians
Citation: Cataldi MP, Lu QL. Ribitol and ribose treatments differentially affect metabolism of muscle tissue in FKRP mutant mice. Sci Rep. 2025;15(1):1329.
Main findings
- The experiment compared quadriceps metabolomics in untreated, ribitol-exposed, and ribose-exposed FKRP-mutant mice.
- Each metabolomics group contained four muscle samples, with two female and two male mice.
- Ribose exposure was associated with increases in ribonate and an advanced glycation end product in this model, while the overall metabolic patterns differed between the two substances.
Practical relevance
- Supports keeping ribose and ribitol evidence separate rather than treating them as interchangeable.
- Provides preclinical safety and biomarker questions for future studies, not a treatment comparison for patients.
Limitations and cautions
- Mouse-model metabolism cannot establish human or pediatric safety, dosing, or effectiveness.
- Very small sample groups and untargeted metabolomics make the findings exploratory.
- The experiment did not test patient function, clinical outcomes, or long-term human exposure.
Primary Sources
Direct links for verification
Primary indexed record for the paper summary on this page.
Publisher DOI landing page.
Full text used to check the animal model, exposure design, metabolomics methods, competing-interest statement, and limitations.
Separate uncontrolled adult case; neither record establishes a pediatric dose or proven clinical benefit.
Related Content
Related routes inside the site
Paper Summary
Quantitative Measurement of Glycosylated Alpha-Dystroglycan as a Biomarker for Disease Severity in LGMD2I/R9
Prospective 12-month observational study of muscle-biopsy glycosylated alpha-dystroglycan measurements in genetically confirmed LGMD2I/R9.
Study Record
AB-1003 Gene Therapy Study in Adults With LGMD2I/R9
Phase 1/2 placebo-controlled gene-therapy study in adults with genetically confirmed FKRP-related LGMD2I/R9.
Study Record
ATA-100 (Formerly GNT0006) Gene Therapy Trial in Patients With LGMDR9
Phase 1 FKRP gene-transfer trial record for ATA-100, designed to assess safety, pharmacodynamics, and immunogenicity with long-term follow-up.